Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Specialty Care Portfolio Total [legacy] — U.S. by Quarter
Specialty Care Portfolio Total [legacy] — U.S. ($M) ($M)
Pfizer Specialty Care Portfolio Total [legacy] — U.S.: $2,157M in Q4 2025, up 3.8% from a year earlier.
Latest, Q4 2025
2,157
Period ended Dec 31, 2025
Change on a year earlier
+3.8%
2,079 in Q4 2024
History
18 quarters
Since Q3 2021
Sources
14
Documents cited below
Where the Q4 2025 figure comes from
“|| Specialty Care | $ | 4,771 | $ | 4,438 | 8% | 6% | $ | 2,157 | $ | 2,079 | 4% | $ | 2,614 | $ | 2,359 | 11% | 8%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Specialty Care Portfolio Total [legacy] — U.S. ($M), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-sc-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.